It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
To examine the comparative robustness of computed tomography (CT)-based conventional radiomics and deep-learning convolutional neural networks (CNN) to predict overall survival (OS) in HCC patients. Retrospectively, 114 HCC patients with pretherapeutic CT of the liver were randomized into a development (n = 85) and a validation (n = 29) cohort, including patients of all tumor stages and several applied therapies. In addition to clinical parameters, image annotations of the liver parenchyma and of tumor findings on CT were available. Cox-regression based on radiomics features and CNN models were established and combined with clinical parameters to predict OS. Model performance was assessed using the concordance index (C-index). Log-rank tests were used to test model-based patient stratification into high/low-risk groups. The clinical Cox-regression model achieved the best validation performance for OS (C-index [95% confidence interval (CI)] 0.74 [0.57–0.86]) with a significant difference between the risk groups (p = 0.03). In image analysis, the CNN models (lowest C-index [CI] 0.63 [0.39–0.83]; highest C-index [CI] 0.71 [0.49–0.88]) were superior to the corresponding radiomics models (lowest C-index [CI] 0.51 [0.30–0.73]; highest C-index [CI] 0.66 [0.48–0.79]). A significant risk stratification was not possible (p > 0.05). Under clinical conditions, CNN-algorithms demonstrate superior prognostic potential to predict OS in HCC patients compared to conventional radiomics approaches and could therefore provide important information in the clinical setting, especially when clinical data is limited.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Institute and Polyclinic for Diagnostic and Interventional Radiology, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)
2 Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Helmholtz-Zentrum Dresden-Rossendorf, OncoRay‑National Center for Radiation Research in Oncology, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)
3 Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Department of Visceral, Thoracic and Vascular Surgery, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257)
4 Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Helmholtz-Zentrum Dresden-Rossendorf, OncoRay‑National Center for Radiation Research in Oncology, Dresden, Germany (GRID:grid.4488.0) (ISNI:0000 0001 2111 7257); National Center for Tumor Diseases (NCT/UCC) Dresden, Dresden, Germany (GRID:grid.461742.2) (ISNI:0000 0000 8855 0365); German Cancer Research Center (DKFZ), Heidelberg, Germany (GRID:grid.7497.d) (ISNI:0000 0004 0492 0584)




